213 related articles for article (PubMed ID: 22645138)
21. The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1.
Liao YC; Si L; deVere White RW; Lo SH
J Cell Biol; 2007 Jan; 176(1):43-9. PubMed ID: 17190795
[TBL] [Abstract][Full Text] [Related]
22. Tensin2 is a novel mediator in thrombopoietin (TPO)-induced cellular proliferation by promoting Akt signaling.
Jung AS; Kaushansky A; Macbeath G; Kaushansky K
Cell Cycle; 2011 Jun; 10(11):1838-44. PubMed ID: 21527831
[TBL] [Abstract][Full Text] [Related]
23. Structure of the C-terminal phosphotyrosine interaction domain of Fe65L1 complexed with the cytoplasmic tail of amyloid precursor protein reveals a novel peptide binding mode.
Li H; Koshiba S; Hayashi F; Tochio N; Tomizawa T; Kasai T; Yabuki T; Motoda Y; Harada T; Watanabe S; Inoue M; Hayashizaki Y; Tanaka A; Kigawa T; Yokoyama S
J Biol Chem; 2008 Oct; 283(40):27165-78. PubMed ID: 18650440
[TBL] [Abstract][Full Text] [Related]
24. Novel functions of CCM1 delimit the relationship of PTB/PH domains.
Zhang J; Dubey P; Padarti A; Zhang A; Patel R; Patel V; Cistola D; Badr A
Biochim Biophys Acta Proteins Proteom; 2017 Oct; 1865(10):1274-1286. PubMed ID: 28698152
[TBL] [Abstract][Full Text] [Related]
25. Nuclear-targeted deleted in liver cancer 1 (DLC1) is less efficient in exerting its tumor suppressive activity both in vitro and in vivo.
Chan LK; Ko FC; Sze KM; Ng IO; Yam JW
PLoS One; 2011; 6(9):e25547. PubMed ID: 21966542
[TBL] [Abstract][Full Text] [Related]
26. Functional interaction of tumor suppressor DLC1 and caveolin-1 in cancer cells.
Du X; Qian X; Papageorge A; Schetter AJ; Vass WC; Liu X; Braverman R; Robles AI; Lowy DR
Cancer Res; 2012 Sep; 72(17):4405-16. PubMed ID: 22693251
[TBL] [Abstract][Full Text] [Related]
27. Integrin beta cytoplasmic domain interactions with phosphotyrosine-binding domains: a structural prototype for diversity in integrin signaling.
Calderwood DA; Fujioka Y; de Pereda JM; García-Alvarez B; Nakamoto T; Margolis B; McGlade CJ; Liddington RC; Ginsberg MH
Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2272-7. PubMed ID: 12606711
[TBL] [Abstract][Full Text] [Related]
28. Tensin2 reduces intracellular phosphatidylinositol 3,4,5-trisphosphate levels at the plasma membrane.
Hafizi S; Gustafsson A; Oslakovic C; Idevall-Hagren O; Tengholm A; Sperandio O; Villoutreix BO; Dahlbäck B
Biochem Biophys Res Commun; 2010 Aug; 399(3):396-401. PubMed ID: 20678486
[TBL] [Abstract][Full Text] [Related]
29. Epidermal growth factor activates the Rho GTPase-activating protein (GAP) Deleted in Liver Cancer 1 via focal adhesion kinase and protein phosphatase 2A.
Ravi A; Kaushik S; Ravichandran A; Pan CQ; Low BC
J Biol Chem; 2015 Feb; 290(7):4149-62. PubMed ID: 25525271
[TBL] [Abstract][Full Text] [Related]
30. The SAM domain of the RhoGAP DLC1 binds EF1A1 to regulate cell migration.
Zhong D; Zhang J; Yang S; Soh UJ; Buschdorf JP; Zhou YT; Yang D; Low BC
J Cell Sci; 2009 Feb; 122(Pt 3):414-24. PubMed ID: 19158340
[TBL] [Abstract][Full Text] [Related]
31. Structure of the PTB domain of tensin1 and a model for its recruitment to fibrillar adhesions.
McCleverty CJ; Lin DC; Liddington RC
Protein Sci; 2007 Jun; 16(6):1223-9. PubMed ID: 17473008
[TBL] [Abstract][Full Text] [Related]
32. The tumor suppressor protein DLC1 is regulated by PKD-mediated GAP domain phosphorylation.
Scholz RP; Gustafsson JO; Hoffmann P; Jaiswal M; Ahmadian MR; Eisler SA; Erlmann P; Schmid S; Hausser A; Olayioye MA
Exp Cell Res; 2011 Feb; 317(4):496-503. PubMed ID: 21087603
[TBL] [Abstract][Full Text] [Related]
33. NMR assignment of the phosphotyrosine binding (PTB) domain of tensin.
Leone M; Yu EC; Liddington R; Pellecchia M
J Biomol NMR; 2006; 36 Suppl 1():40. PubMed ID: 16705357
[No Abstract] [Full Text] [Related]
34. Functional cross-talk between ras and rho pathways: a Ras-specific GTPase-activating protein (p120RasGAP) competitively inhibits the RhoGAP activity of deleted in liver cancer (DLC) tumor suppressor by masking the catalytic arginine finger.
Jaiswal M; Dvorsky R; Amin E; Risse SL; Fansa EK; Zhang SC; Taha MS; Gauhar AR; Nakhaei-Rad S; Kordes C; Koessmeier KT; Cirstea IC; Olayioye MA; Häussinger D; Ahmadian MR
J Biol Chem; 2014 Mar; 289(10):6839-6849. PubMed ID: 24443565
[TBL] [Abstract][Full Text] [Related]
35. A phosphorylation switch controls the spatiotemporal activation of Rho GTPases in directional cell migration.
Cao X; Kaneko T; Li JS; Liu AD; Voss C; Li SS
Nat Commun; 2015 Jul; 6():7721. PubMed ID: 26166433
[TBL] [Abstract][Full Text] [Related]
36. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma.
Wong CM; Yam JW; Ching YP; Yau TO; Leung TH; Jin DY; Ng IO
Cancer Res; 2005 Oct; 65(19):8861-8. PubMed ID: 16204057
[TBL] [Abstract][Full Text] [Related]
37. The PTB domain of tensin: NMR solution structure and phosphoinositides binding studies.
Leone M; Yu EC; Liddington RC; Pasquale EB; Pellecchia M
Biopolymers; 2008 Jan; 89(1):86-92. PubMed ID: 17922498
[TBL] [Abstract][Full Text] [Related]
38. Regulation of deleted in liver cancer 1 tumor suppressor by protein-protein interactions and phosphorylation.
Ko FC; Ping Yam JW
Int J Cancer; 2014 Jul; 135(2):264-9. PubMed ID: 24114040
[TBL] [Abstract][Full Text] [Related]
39. DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism.
Yang X; Popescu NC; Zimonjic DB
Cancer Res; 2011 Apr; 71(8):2916-25. PubMed ID: 21372205
[TBL] [Abstract][Full Text] [Related]
40. Crystal structure of the human Fe65-PTB1 domain.
Radzimanowski J; Ravaud S; Schlesinger S; Koch J; Beyreuther K; Sinning I; Wild K
J Biol Chem; 2008 Aug; 283(34):23113-20. PubMed ID: 18550529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
